The Prostate Cancer Community Assistance, Research and Education Act of 2022 (H.R. 7750)

What does this bill do?
The Prostate Cancer Community Assistance, Research and Education Act of 2022, or the PC-CARE Act (H.R. 7750), led by Representatives Greg Murphy (NC-03) and Bobby Rush (IL-01), would establish a Prostate Cancer Coordinating Committee to monitor, coordinate, and evaluate the activities of Federal prostate cancer research programs.

Why is this bill important?
A broad range of Federal agencies support prostate cancer research, including the NIH, CDC, DoD and VA. To efficiently steward these federal investments and move toward a cure as quickly as possible, it is vital to ensure that the various federal programs are coordinated to best fill research gaps, delineate research priorities, and prioritize the most critical work. This bill will require Federal agencies participating in prostate cancer research to meet regularly together, and with the largest private funders of prostate cancer research, to chart a path to fight against this disease.

Why prostate cancer?
Prostate cancer is the second leading cause of cancer death among American men and is the most commonly diagnosed; 1 in 8 American men will be diagnosed with prostate cancer during their lifetime. The American Cancer Society estimates that 268,490 men will be told they have prostate cancer in 2022. Currently, over 3.1 million American men are living with the disease – more than the population of Chicago, America's third-largest city.

Who will be on this committee?

A maximum of 24 members, each serving a 3-year term

- Cancer Researchers
- Clinicians
- Patients & Caregivers
- Patient Groups
- Professional Medical Societies
- National Institutes of Health
- Centers for Disease Control and Prevention
- Food and Drug Administration
- Department of Defense
- Department of Veterans Affairs
- Centers for Medicare & Medicaid Services
- Health Resources & Services Administration

Zerocancer.org